Skip to content

Intra Articular Ozone or Hyaluronic Acid Injection: Which One is Superior in Patients with Knee Osteoarthritis? a 6-Month Randomized Clinical Trial

Intra Articular Ozone or Hyaluronic Acid Injection: Which One is Superior in Patients with Knee Osteoarthritis? a 6-Month Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017041513442N16
Enrollment
174
Registered
2017-08-28
Start date
2016-01-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Gonarthrosis [arthrosis of knee]

Interventions

Intervention 1: Intervention group 1: Hyaluronic acid, knee intraarticuar injection, 20mg/2ml solution, 3 times, 1 week interval. Intervention 2: Intervention group 2: Ozone-Oxygen solution, knee intr
Treatment - Drugs
Intervention group 1: Hyaluronic acid, knee intraarticuar injection, 20mg/2ml solution, 3 times, 1 week interval
Intervention group 2: Ozone-Oxygen solution, knee intraarticuar injection, 10 milliliter, 3 times, 1 week interval

Sponsors

Physical Medicine and Rehabilitation Department of Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: age between 45-75 years; symptomatic knee OA with the pain aggravated by weight bearing; symptoms lasting for at least 6 months despite conservative treatments; Kellgren-Lawrance radiologic scoring (KLS) system scores ranging from 2-3 Exclusion Criteria: history of trauma, surgery or any invasive procedure in the affected joint during the past 6 months; mal-alignment in lower limbs and abnormal blood count or impaired coagulation tests; pregnant women; patients who were under immunosuppressant treatments; those with an underlying systemic arthropathy (secondary OA); patients being treated with angiotensin converting enzyme inhibitors (ACEI) and significant deficiency in glucose 6-phosphate dehydrogenase (G6PD) level

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Patient Function. Timepoint: before intervention & 6 months after intervention. Method of measurement: WOMAC questionnaire.;Knee pain. Timepoint: before intervention & 6 months after intervention. Method of measurement: VAS.;Joint stiffness. Timepoint: before intervention & 6 months after intervention. Method of measurement: WOMAC questionnaire.

Primary

MeasureTime frame
Knee pain. Timepoint: before intervention & 6 months after last intervention. Method of measurement: WOMAC questionnair.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Rahimi Dehgolan

Physical Medicine and Rehabilitation Department, Shahid Beheshti University of Medical Sciences, Sch

shahram.rahimi.dehgolan@gmail.com+98 21 2273 1112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026